Neurotrophin	0	12	B-Gene_or_gene_product
p75	13	16	I-Gene_or_gene_product
receptor	17	25	I-Gene_or_gene_product
(	26	27	O
p75NTR	27	33	B-Gene_or_gene_product
)	33	34	O
promotes	35	43	O
endothelial	44	55	B-Cell
cell	56	60	I-Cell
apoptosis	61	70	O
and	71	74	O
inhibits	75	83	O
angiogenesis	84	96	O
:	96	97	O
implications	98	110	O
for	111	114	O
diabetes	115	123	O
-	123	124	O
induced	124	131	O
impaired	132	140	O
neovascularization	141	159	O
in	160	162	O
ischemic	163	171	O
limb	172	176	B-Organ
muscles	177	184	I-Organ
.	184	185	O

Diabetes	187	195	O
impairs	196	203	O
endothelial	204	215	B-Cell
function	216	224	O
and	225	228	O
reparative	229	239	O
neovascularization	240	258	O
.	258	259	O

The	260	263	O
p75	264	267	B-Gene_or_gene_product
receptor	268	276	I-Gene_or_gene_product
of	277	279	I-Gene_or_gene_product
neurotrophins	280	293	I-Gene_or_gene_product
(	294	295	O
p75	295	298	B-Gene_or_gene_product
(	298	299	I-Gene_or_gene_product
NTR	299	302	I-Gene_or_gene_product
)	302	303	I-Gene_or_gene_product
)	303	304	O
,	304	305	O
which	306	311	O
is	312	314	O
scarcely	315	323	O
present	324	331	O
in	332	334	O
healthy	335	342	O
endothelial	343	354	B-Cell
cells	355	360	I-Cell
(	361	362	O
ECs	362	365	B-Cell
)	365	366	O
,	366	367	O
becomes	368	375	O
strongly	376	384	O
expressed	385	394	O
by	395	397	O
capillary	398	407	B-Cell
ECs	408	411	I-Cell
after	412	417	O
induction	418	427	O
of	428	430	O
peripheral	431	441	O
ischemia	442	450	O
in	451	453	O
type	454	458	O
-	458	459	O
1	459	460	O
diabetic	461	469	O
mice	470	474	B-Organism
.	474	475	O

Here	476	480	O
,	480	481	O
we	482	484	O
show	485	489	O
that	490	494	O
gene	495	499	O
transfer	500	508	O
-	508	509	O
induced	509	516	O
p75	517	520	B-Gene_or_gene_product
(	520	521	I-Gene_or_gene_product
NTR	521	524	I-Gene_or_gene_product
)	524	525	I-Gene_or_gene_product
expression	526	536	O
impairs	537	544	O
the	545	548	O
survival	549	557	O
,	557	558	O
proliferation	559	572	O
,	572	573	O
migration	574	583	O
,	583	584	O
and	585	588	O
adhesion	589	597	O
capacities	598	608	O
of	609	611	O
cultured	612	620	O
ECs	621	624	B-Cell
and	625	628	O
endothelial	629	640	B-Cell
progenitor	641	651	I-Cell
cells	652	657	I-Cell
(	658	659	O
EPCs	659	663	B-Cell
)	663	664	O
and	665	668	O
inhibits	669	677	O
angiogenesis	678	690	O
in	691	693	O
vitro	694	699	O
.	699	700	O

Moreover	701	709	O
,	709	710	O
intramuscular	711	724	O
p75	725	728	B-Gene_or_gene_product
(	728	729	I-Gene_or_gene_product
NTR	729	732	I-Gene_or_gene_product
)	732	733	I-Gene_or_gene_product
gene	734	738	O
delivery	739	747	O
impairs	748	755	O
neovascularization	756	774	O
and	775	778	O
blood	779	784	B-Organism_substance
flow	785	789	O
recovery	790	798	O
in	799	801	O
a	802	803	O
mouse	804	809	B-Organism
model	810	815	O
of	816	818	O
limb	819	823	B-Organism_subdivision
ischemia	824	832	O
.	832	833	O

These	834	839	O
disturbed	840	849	O
functions	850	859	O
are	860	863	O
associated	864	874	O
with	875	879	O
suppression	880	891	O
of	892	894	O
signaling	895	904	O
mechanisms	905	915	O
implicated	916	926	O
in	927	929	O
EC	930	932	B-Cell
survival	933	941	O
and	942	945	O
angiogenesis	946	958	O
.	958	959	O

In	960	962	O
fact	963	967	O
,	967	968	O
p75	969	972	B-Gene_or_gene_product
(	972	973	I-Gene_or_gene_product
NTR	973	976	I-Gene_or_gene_product
)	976	977	I-Gene_or_gene_product
depresses	978	987	O
the	988	991	O
VEGF	992	996	B-Gene_or_gene_product
-	996	997	I-Gene_or_gene_product
A	997	998	I-Gene_or_gene_product
/	998	999	O
Akt	999	1002	B-Gene_or_gene_product
/	1002	1003	O
eNOS	1003	1007	B-Gene_or_gene_product
/	1007	1008	O
NO	1008	1010	B-Drug_or_compound
pathway	1011	1018	O
and	1019	1022	O
additionally	1023	1035	O
reduces	1036	1043	O
the	1044	1047	O
mRNA	1048	1052	O
levels	1053	1059	O
of	1060	1062	O
ITGB1	1063	1068	B-Gene_or_gene_product
[	1069	1070	O
beta	1070	1074	B-Gene_or_gene_product
(	1075	1076	I-Gene_or_gene_product
1	1076	1077	I-Gene_or_gene_product
)	1077	1078	I-Gene_or_gene_product
integrin	1079	1087	I-Gene_or_gene_product
]	1087	1088	O
,	1088	1089	O
BIRC5	1090	1095	B-Gene_or_gene_product
(	1096	1097	O
survivin	1097	1105	B-Gene_or_gene_product
)	1105	1106	O
,	1106	1107	O
PTTG1	1108	1113	B-Gene_or_gene_product
(	1114	1115	O
securin	1115	1122	B-Gene_or_gene_product
)	1122	1123	O
and	1124	1127	O
VEZF1	1128	1133	B-Gene_or_gene_product
.	1133	1134	O

Diabetic	1135	1143	O
mice	1144	1148	B-Organism
,	1148	1149	O
which	1150	1155	O
typically	1156	1165	O
show	1166	1170	O
impaired	1171	1179	O
postischemic	1180	1192	O
muscular	1193	1201	O
neovascularization	1202	1220	O
and	1221	1224	O
blood	1225	1230	B-Organism_substance
perfusion	1231	1240	O
recovery	1241	1249	O
,	1249	1250	O
have	1251	1255	O
these	1256	1261	O
defects	1262	1269	O
corrected	1270	1279	O
by	1280	1282	O
intramuscular	1283	1296	O
gene	1297	1301	O
transfer	1302	1310	O
of	1311	1313	O
a	1314	1315	O
dominant	1316	1324	O
negative	1325	1333	O
mutant	1334	1340	O
form	1341	1345	O
of	1346	1348	O
p75	1349	1352	B-Gene_or_gene_product
(	1352	1353	I-Gene_or_gene_product
NTR	1353	1356	I-Gene_or_gene_product
)	1356	1357	I-Gene_or_gene_product
.	1357	1358	O

Collectively	1359	1371	O
,	1371	1372	O
our	1373	1376	O
data	1377	1381	O
newly	1382	1387	O
demonstrate	1388	1399	O
the	1400	1403	O
antiangiogenic	1404	1418	O
action	1419	1425	O
of	1426	1428	O
p75	1429	1432	B-Gene_or_gene_product
(	1432	1433	I-Gene_or_gene_product
NTR	1433	1436	I-Gene_or_gene_product
)	1436	1437	I-Gene_or_gene_product
and	1438	1441	O
open	1442	1446	O
new	1447	1450	O
avenues	1451	1458	O
for	1459	1462	O
the	1463	1466	O
therapeutic	1467	1478	O
use	1479	1482	O
of	1483	1485	O
p75	1486	1489	B-Gene_or_gene_product
(	1489	1490	I-Gene_or_gene_product
NTR	1490	1493	I-Gene_or_gene_product
)	1493	1494	I-Gene_or_gene_product
inhibition	1495	1505	O
to	1506	1508	O
combat	1509	1515	O
diabetes	1516	1524	O
-	1524	1525	O
induced	1525	1532	O
microvascular	1533	1546	B-Tissue
liabilities	1547	1558	O
.	1558	1559	O

